Beyond immunochemotherapy: Combinations of rituximab with cytokines interferon-α2a and granulocyte-macrophage colony stimulating factor
- 30 April 2002
- journal article
- review article
- Published by Elsevier in Seminars in Oncology
- Vol. 29 (2) , 7-10
- https://doi.org/10.1053/sonc.2002.32747
Abstract
No abstract availableKeywords
This publication has 14 references indexed in Scilit:
- Immunochemotherapy in indolent non-Hodgkin's lymphomaSeminars in Oncology, 2002
- Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: clinical and molecular evaluationBlood, 2001
- Rituximab Anti-CD20 Monoclonal Antibody Therapy in Non-Hodgkin’s Lymphoma: Safety and Efficacy of Re-TreatmentJournal of Clinical Oncology, 2000
- Effect of interferon-α on CD20 antigen expression of B–cell chronic lymphocytic leukemiaCytokines, Cellular & Molecular Therapy, 2000
- Single-Agent Monoclonal Antibody Efficacy in Bulky Non-Hodgkin's Lymphoma: Results of a Phase II Trial of RituximabJournal of Clinical Oncology, 1999
- Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program.Journal of Clinical Oncology, 1998
- Comparison in low-tumor-burden follicular lymphomas between an initial no-treatment policy, prednimustine, or interferon alfa: a randomized study from the Groupe d'Etude des Lymphomes Folliculaires. Groupe d'Etude des Lymphomes de l'Adulte.Journal of Clinical Oncology, 1997
- The Natural History of Initially Untreated Low-Grade Non-Hodgkin's LymphomasNew England Journal of Medicine, 1984
- Augmentation of Human K‐Cell Activity with InterferonScandinavian Journal of Immunology, 1980
- Augmentation by interferon of human natural and antibody-dependent cell-mediated cytotoxicityNature, 1979